Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 24,321 | 41,317 | 59,557 | 51,540 | 39,864 |
| Marketable Securities | 176,648 | 203,669 | 228,652 | 188,590 | 235,863 |
| Receivables | 28,662 | 25,347 | 36,451 | 25,126 | 9,303 |
| Inventories | 8,817 | 8,369 | 7,782 | 8,738 | 7,270 |
| TOTAL | $245,236 | $284,896 | $338,863 | $281,436 | $303,860 |
| Non-Current Assets | |||||
| PPE Net | 2,285 | 2,465 | 1,209 | 1,075 | 1,075 |
| Investments And Advances | 23,221 | 23,053 | 13,645 | 13,374 | 11,939 |
| Intangibles | 14,176 | 14,452 | 14,729 | 12,972 | 7,241 |
| Other Non-Current Assets | 2,653 | 2,786 | 4,357 | 4,615 | 3,203 |
| TOTAL | $42,335 | $42,756 | $33,940 | $32,036 | $23,458 |
| Total Assets | $287,571 | $327,652 | $372,803 | $313,472 | $327,318 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 48,263 | 37,948 | 49,768 | 44,264 | 27,009 |
| Other current liabilities | 1,349 | 1,197 | 526 | 746 | 540 |
| TOTAL | $49,612 | $39,145 | $50,877 | $45,599 | $27,622 |
| Non-Current Liabilities | |||||
| Long Term Debt | 171,195 | 168,514 | 168,273 | 71,959 | 69,383 |
| Other Non-Current Liabilities | 5,456 | 5,735 | 5,998 | 3,593 | 1,339 |
| TOTAL | $176,651 | $174,249 | $174,271 | $75,552 | $70,722 |
| Total Liabilities | $226,263 | $213,394 | $225,148 | $121,151 | $98,344 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 99,303 | 99,297 | 98,849 | 98,826 | 98,214 |
| Common Shares | 10 | 10 | 10 | 10 | 10 |
| Retained earnings | -355,221 | -294,603 | -253,279 | -202,128 | -157,245 |
| Other shareholders' equity | -96 | 125 | -7 | -46 | 72 |
| TOTAL | $61,308 | $114,258 | $147,655 | $192,321 | $228,974 |
| Total Liabilities And Equity | $287,571 | $327,652 | $372,803 | $313,472 | $327,318 |